PK Study of Gefurulimab SC in Healthy Chinese Adult Participants

Study Identifier:
D6780C00003
ClinicalTrials.gov Identifier:
NCT06677138
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
1-855-752-2356 or [email protected]
Recruiting

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: gefurulimab
Date
Oct 2024 - Mar 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 45 Years
Requirements Information
Sex
Female & Male
Age
18 - 45 Years

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: gefurulimab
Date
Oct 2024 - Mar 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 45 Years years
Requirements Information

Protocol Summary

The primary objective of this study is to characterize the PK properties of a single dose of gefurulimab in healthy Chinese participants.

Trial Locations

Location
Status
Location
Research Site
Shanghai, China, 201107
Status
Recruiting